234 related articles for article (PubMed ID: 32366855)
1. The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.
Ye S; Xu P; Huang M; Chen X; Zeng S; Wang Q; Chen J; Li K; Gao W; Liu R; Liu J; Shao Y; Zhang H; Xu Y; Zhang Q; Zhong Z; Wei Z; Wang J; Hao B; Huang W; Liu Q
Cell Death Dis; 2020 May; 11(5):312. PubMed ID: 32366855
[TBL] [Abstract][Full Text] [Related]
2. Reductive carboxylation supports redox homeostasis during anchorage-independent growth.
Jiang L; Shestov AA; Swain P; Yang C; Parker SJ; Wang QA; Terada LS; Adams ND; McCabe MT; Pietrak B; Schmidt S; Metallo CM; Dranka BP; Schwartz B; DeBerardinis RJ
Nature; 2016 Apr; 532(7598):255-8. PubMed ID: 27049945
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
[TBL] [Abstract][Full Text] [Related]
4. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
5. α-Lactalbumin-oleic acid complex kills tumor cells by inducing excess energy metabolism but inhibiting mRNA expression of the related enzymes.
Fang B; Zhang M; Ge KS; Xing HZ; Ren FZ
J Dairy Sci; 2018 Jun; 101(6):4853-4863. PubMed ID: 29550120
[TBL] [Abstract][Full Text] [Related]
6. The nitroxide Tempol modulates anthracycline resistance in breast cancer cells.
Gariboldi MB; Terni F; Ravizza R; Meschini S; Marra M; Condello M; Arancia G; Monti E
Free Radic Biol Med; 2006 Apr; 40(8):1409-18. PubMed ID: 16631531
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy.
Ju R; Fei K; Li S; Chen C; Zhu L; Li J; Zhang D; Guo L; Ye C
J Pharmacol Exp Ther; 2018 Oct; 367(1):20-27. PubMed ID: 30002095
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
[TBL] [Abstract][Full Text] [Related]
9. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
[TBL] [Abstract][Full Text] [Related]
10. 3-Bromopyruvic Acid Inhibits Tricarboxylic Acid Cycle and Glutaminolysis in HepG2 Cells.
Jardim-Messeder D; Moreira-Pacheco F
Anticancer Res; 2016 May; 36(5):2233-41. PubMed ID: 27127128
[TBL] [Abstract][Full Text] [Related]
11. Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
Zhang GF; Jensen MV; Gray SM; El K; Wang Y; Lu D; Becker TC; Campbell JE; Newgard CB
Cell Metab; 2021 Apr; 33(4):804-817.e5. PubMed ID: 33321098
[TBL] [Abstract][Full Text] [Related]
12. Osmundacetone modulates mitochondrial metabolism in non-small cell lung cancer cells by hijacking the glutamine/glutamate/α-KG metabolic axis.
Yang Y; He P; Hou Y; Liu Z; Zhang X; Li N
Phytomedicine; 2022 Jun; 100():154075. PubMed ID: 35413646
[TBL] [Abstract][Full Text] [Related]
13. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4.
Wang L; Zhou H; Wang Y; Cui G; Di LJ
Cell Death Dis; 2015 Jan; 6(1):e1620. PubMed ID: 25633289
[TBL] [Abstract][Full Text] [Related]
14. Redox control of glutamine utilization in cancer.
Alberghina L; Gaglio D
Cell Death Dis; 2014 Dec; 5(12):e1561. PubMed ID: 25476909
[TBL] [Abstract][Full Text] [Related]
15. Identification of active elementary flux modes in mitochondria using selectively permeabilized CHO cells.
Nicolae A; Wahrheit J; Nonnenmacher Y; Weyler C; Heinzle E
Metab Eng; 2015 Nov; 32():95-105. PubMed ID: 26417715
[TBL] [Abstract][Full Text] [Related]
16. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
Grassian AR; Parker SJ; Davidson SM; Divakaruni AS; Green CR; Zhang X; Slocum KL; Pu M; Lin F; Vickers C; Joud-Caldwell C; Chung F; Yin H; Handly ED; Straub C; Growney JD; Vander Heiden MG; Murphy AN; Pagliarini R; Metallo CM
Cancer Res; 2014 Jun; 74(12):3317-31. PubMed ID: 24755473
[TBL] [Abstract][Full Text] [Related]
17. Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells.
Li W; Zhao Y
Cancer Sci; 2013 Feb; 104(2):143-8. PubMed ID: 23107437
[TBL] [Abstract][Full Text] [Related]
18. Triptolide inhibits tumor growth by induction of cellular senescence.
Li R; Zhang X; Tian X; Shen C; Zhang Q; Zhang Y; Wang Z; Wang F; Tao Y
Oncol Rep; 2017 Jan; 37(1):442-448. PubMed ID: 27878302
[TBL] [Abstract][Full Text] [Related]
19. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
[TBL] [Abstract][Full Text] [Related]
20. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle.
Gameiro PA; Laviolette LA; Kelleher JK; Iliopoulos O; Stephanopoulos G
J Biol Chem; 2013 May; 288(18):12967-77. PubMed ID: 23504317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
